乐普生物-B(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02157 乐普生物-B

未开盘 05-07 16:08:11

5.230

+0.090

+1.75%

最高5.460	最低5.150	成交量971.34万
今开5.280	昨收5.140	日振幅6.03%
总市值94.35亿	流通市值94.35亿	总股本18.04亿
成交额5,142万	换手率0.54%	流通股本18.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02157","market":"HK","secType":"STK","nameCN":"乐普生物-B","latestPrice":5.23,"timestamp":1778141291004,"preClose":5.14,"halted":0,"volume":9713400,"delay":0,"changeRate":0.01750972762645929,"floatShares":1804000000,"shares":1804000000,"eps":0.17139951169347886,"marketStatus":"未开盘","change":0.09,"latestTime":"05-07 16:08:11","open":5.28,"high":5.46,"low":5.15,"amount":51416311,"amplitude":0.060311,"askPrice":5.24,"askSize":3000,"bidPrice":5.23,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":0.17139951169347886,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778203800000},"marketStatusCode":0,"adr":0,"listingDate":1645545600000,"exchange":"SEHK","adjPreClose":5.14,"openAndCloseTimeList":[[1778117400000,1778126400000],[1778130000000,1778140800000]],"volumeRatio":1.503236,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02157","defaultTab":"news","newsList":[{"id":"1117370152","title":"乐普生物-B4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1117370152","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117370152?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:56","pubTimestamp":1778144162,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司于2026年5月7日公布了2026年4月的证券变动月报表。根据公告，截至2026年4月末，公司已发行普通股合计1,804,439,838股，与上月持平，注册股本总额为人民币1,804,439,838元，面值每股1元。公告显示，报告期内未发生新股发行、购回或注销事项，也无新增或已行使的股份期权及其他股权激励计划安排。公告同时披露，公司截至4月底满足香港联交所的公众持股量要求，该等股份在数量及权利方面保持一致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633133962","title":"乐普生物-B：5月11日起简称改为“乐普生物”","url":"https://stock-news.laohu8.com/highlight/detail?id=2633133962","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633133962?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:11","pubTimestamp":1778069460,"startTime":"0","endTime":"0","summary":"5月6日，乐普生物-B（02157）发布公告，宣布香港联合交易所已批准上市规则第18A.09至18A.11条不适用本公司。自2026年5月11日起，本公司的中英文简称将不再加上标记“B”，股份将以新英文股份简称“LEPUBIO”和中文股份简称“乐普生物”在联交所买卖，股份代号仍为“2157”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605063728876463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630397311","title":"乐普生物-B(02157)拟委任范馨予为监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2630397311","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630397311?lang=zh_cn&edition=full","pubTime":"2026-04-27 21:47","pubTimestamp":1777297629,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物-B(02157)发布公告，董事会建议委任范馨予女士(范女士)为监事。倘获股东于股东周年大会上批准，彼之任期将自相关决议案于股东周年大会上获通过之日起至第二届董事会任期届满之日止，惟于彼的任期届满后可膺选连任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159998665","title":"乐普生物-B(02157)2025年收入同比增逾150%成功扭亏，ADC管线与国际化布局加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1159998665","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159998665?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:29","pubTimestamp":1776860993,"startTime":"0","endTime":"0","summary":"截至2025年12月31日止年度，乐普生物-B实现收入约人民币9.35亿元，较2024年的3.68亿元同比增长154.19%，并录得年内利润人民币2.59亿元，相较上一年度亏损4.24亿元显著改善。销售成本约人民币8,960万元，研发开支约人民币4.01亿元，占主要投入比例，较2024年度的4.38亿元有所下降。毛利率由上年的约79.66%提升至超过90%，显示盈利能力增强。核心商业化产品包括普枸单抗注射液和EGFR靶向ADC美佑恒，销售端实现约人民币5.01亿元收入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"乐普生物-B(02157)2025年收入同比增逾150%成功扭亏，ADC管线与国际化布局加速推进","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625164562","title":"滨会生物冲刺港股：年亏1.2亿 乐普生物与扬子江药业是股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2625164562","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625164562?lang=zh_cn&edition=full","pubTime":"2026-04-05 14:23","pubTimestamp":1775370219,"startTime":"0","endTime":"0","summary":"武汉滨会生物科技股份有限公司（简称：“滨会生物”）日前更新招股书，准备在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260405/6391099581624874437279093.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260405/6391099581624874437279093.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33196/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK1161","BK4588","BK4585","VXUS","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1191","01530","02162","BK1583","09969","09995","LU2328871848.SGD","02157","06978","06955","BK1574","01477","BK1161","02637","159992","LU1969619763.USD","HK0000165453.HKD","BK1587","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157446883","title":"异动解读 | 乐普生物-B盘中大涨9.13%，创新药概念走强受BD与业绩催化及AACR年会预期推动","url":"https://stock-news.laohu8.com/highlight/detail?id=1157446883","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157446883?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:57","pubTimestamp":1774591020,"startTime":"0","endTime":"0","summary":"乐普生物-B今日盘中大涨9.13%，引起了市场的广泛关注。消息面上，创新药概念板块整体走强。行业数据显示，今年以来创新药出海业务发展（BD）持续高景气，总交易金额已超过去年全年水平，为板块提供了强劲动力。同时，近期多家同行业药企披露了亮眼的年度业绩，增强了市场对整个创新药行业盈利兑现能力的信心。此外，即将召开的美国癌症研究协会（AACR）年会上，预计将有大量中国药企携创新药产品亮相并发布重要临床数据，这一前瞻性事件也提振了市场对包括乐普生物-B在内的创新药企业的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2e01cbc0eb24c402eed6076bf7c5c222","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622882066","title":"强业绩提振，港股通创新药逆市续涨，520880收复20日线！乐普生物-B绩后狂飙14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882066","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622882066?lang=zh_cn&edition=full","pubTime":"2026-03-26 11:03","pubTimestamp":1774494180,"startTime":"0","endTime":"0","summary":"3月26日，港股通医药再度逆市表现，100%创新药研发标的——港股通创新药ETF华宝、港股医疗核心资产——港股通医疗ETF华宝双双高开，一度携手涨超1%！520880量价齐升，盘中收复20日线，实时成交超2亿元。　　创新药多股领跑，乐普生物-B盘中飙升逾14%站上半年线，领涨所有港股通标的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-26/doc-inhshtfa2929921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02157","BK1161","520880","BK4585","BK4588","VXUS","159992","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139201214","title":"异动解读 | 乐普生物-B盘中大涨6.71%，业绩利好推动股价上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=1139201214","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139201214?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:41","pubTimestamp":1774489266,"startTime":"0","endTime":"0","summary":"乐普生物-B今日盘中股价大幅上涨6.71%，引发市场关注。报告期内，公司实现收入9.35亿元人民币，同比大幅增长154.19%；公司拥有人应占利润达到2.61亿元，成功实现同比扭亏为盈。此外，于2025年10月获批上市的新产品美佑恒在报告期内已贡献初步收入，进一步丰富了公司的商业化产品组合，为未来增长奠定了坚实基础。公司全球首创的EGFR靶向ADC药物美佑恒已在中国获批上市，同时有更多候选药物进入关键临床阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622026892","title":"乐普生物-B(02157)发布年度业绩 股东应占利润2.61亿元 同比扭亏为盈 更多候选药物进入关键临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2622026892","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622026892?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:40","pubTimestamp":1774428001,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物-B 发布截至2025年12月31日止年度业绩，该集团期内取得收入9.35亿元人民币，同比增加154.19%;公司拥有人应占利润2.61亿元，同比扭亏为盈;每股基本盈利0.15元。最值得注意的是，于2025年，集团的全球首创EGFR靶向ADC美佑恒已在中国获得上市批准。同时，集团有更多候选药物进入关键临床阶段，且通过开发及优化联合治疗方案实现了治疗线数前移。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"乐普生物-B(02157)发布年度业绩 股东应占利润2.61亿元 同比扭亏为盈 更多候选药物进入关键临床阶段","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618928386","title":"乐普生物-B(02157.HK)拟3月25日举行董事会会议审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618928386","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618928386?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:17","pubTimestamp":1773235023,"startTime":"0","endTime":"0","summary":"格隆汇3月11日丨乐普生物-B(02157.HK)宣布，董事会会议将于2026年3月25日(星期三)举行，藉以(其中包括)考虑及批准公司及其附属公司截至2025年12月31日止年度的年度业绩及其发布，并考虑建议派发末期股息(如有)，以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260311/32060963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618396730","title":"乐普生物-B(02157)：AstraZeneca已支付4500万美元里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2618396730","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618396730?lang=zh_cn&edition=full","pubTime":"2026-03-11 06:46","pubTimestamp":1773182804,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物-B 发布公告，于2023年2月，KYM Biosciences Inc.与AstraZeneca已订立全球独家许可协议，以开发及商业化CMG901。根据许可协议条款及条件的规限下，上述临床试验完成首例受试者给药已触发相关里程碑付款，总金额为4500万美元。AstraZeneca已支付该里程碑款项。KYM为由该公司与康诺亚成立的合营企业，由该公司及康诺亚分别持有30%及70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618962123","title":"乐普生物-B(02157)发盈喜 预计归母净利润将不少于2.00亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2618962123","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618962123?lang=zh_cn&edition=full","pubTime":"2026-03-11 06:21","pubTimestamp":1773181278,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物-B 发布公告，预计公司截至2025年12月31日止年度(报告期)归属于股东的净利润将不少于人民币2.00亿元，较截至2024年12月31日止年度的亏损约人民币4.11亿元增加不少于人民币6.11亿元。该变动乃由于公司不再对被投资公司拥有重大影响力。该等收益属非经常性及非经营性质。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"乐普生物-B(02157)发盈喜 预计归母净利润将不少于2.00亿元 同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125918373","title":"乐普生物-B预计2025财年业绩提升，普佑恒与美佑恒获NMPA批准后十月起贡献收入增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1125918373","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125918373?lang=zh_cn&edition=full","pubTime":"2026-03-11 06:11","pubTimestamp":1773180666,"startTime":"0","endTime":"0","summary":"乐普生物-B（股票代码：02157）预计2025财年业绩将显著改善，主要得益于其核心产品普佑恒（Puyouheng）与美佑恒（Meiyouheng）在获得国家药品监督管理局（NMPA）批准后，自2025年10月起带来的收入增长。此外，公司其他业务板块也有望在财年内提供额外业绩支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122780693","title":"乐普生物-B 2025财年营收显著增长，经调整净利润2.00亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122780693","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122780693?lang=zh_cn&edition=full","pubTime":"2026-03-11 06:10","pubTimestamp":1773180654,"startTime":"0","endTime":"0","summary":"2026年3月11日，乐普生物-B公告显示，截至2025年12月31日止财政年度，公司实现归属于股东的经调整净利润不少于人民币2.00亿元，而上一年度则录得亏损约人民币4.11亿元，净利润同比增加不少于人民币6.11亿元。其中，普佑恒贡献稳定收入，而美佑恒自2025年10月获得国家药监局批准后也实现初步收入。公司表示，普佑恒、美佑恒等核心产品将持续贡献营收增量，而对外许可业务也将成为主营收入的重要来源。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618600406","title":"乐普生物-B盘中异动 股价大涨5.17%报4.680港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618600406","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618600406?lang=zh_cn&edition=full","pubTime":"2026-03-10 10:06","pubTimestamp":1773108367,"startTime":"0","endTime":"0","summary":"2026年03月10日早盘10时06分，乐普生物-B股票出现波动，股价急速上涨5.17%。截至发稿，该股报4.680港元/股，成交量369.6万股，换手率0.20%，振幅9.21%。资金方面，该股资金流入984.952万港元，流出382.588万港元。乐普生物-B股票所在的生物技术行业中，整体涨幅为4.03%。乐普生物-B公司简介：乐普生物科技股份有限公司是一家专注于肿瘤治疗领域的中国生物制药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310100607a45cfb3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310100607a45cfb3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618477600","title":"每日卖空追踪 | 乐普生物-B 03月09日卖空量成交33.8万股，卖空比例为3.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618477600","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618477600?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045028,"startTime":"0","endTime":"0","summary":"乐普生物-B北京时间03月09日，涨1.37%，卖空量成交33.8万股，较上一交易日减少50.22%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163346a6b1c771&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163346a6b1c771&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618004016","title":"乐普生物-B03月09日获主力加仓624.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618004016","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618004016?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:15","pubTimestamp":1773044121,"startTime":"0","endTime":"0","summary":"03月09日, 乐普生物-B股价涨1.37%，报收4.45元，成交金额4253.3万元，换手率0.54%，振幅7.06%，量比1.12。乐普生物-B今日主力资金净流入624.0万元，上一交易日主力净流入635.5万元。该股近5个交易日上涨7.19%，主力资金累计净流入1182.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入343.6万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161608a6b1b33e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161608a6b1b33e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617378651","title":"每日卖空追踪 | 乐普生物-B 03月06日卖空量成交45万股，卖空比例为4.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617378651","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617378651?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:30","pubTimestamp":1772785827,"startTime":"0","endTime":"0","summary":"乐普生物-B北京时间03月06日，涨5.28%，卖空量成交45万股，较上一交易日减少41.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163328a6aa3d24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163328a6aa3d24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617517926","title":"乐普生物-B03月06日主力净流入635.5万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517926","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617517926?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:15","pubTimestamp":1772784952,"startTime":"0","endTime":"0","summary":"03月06日, 乐普生物-B股价涨5.28%，报收4.39元，成交金额4267.6万元，换手率0.55%，振幅8.39%，量比1.18。乐普生物-B今日主力资金净流入635.5万元，上一交易日主力净流出232.1万元。该股近5个交易日下跌4.42%，主力资金累计净流入262.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出203.1万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306162021a6aa2e39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306162021a6aa2e39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lepubiopharma.com","stockEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":-0.1496},{"period":"3month","weight":0.1104},{"period":"6month","weight":-0.1014},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0523}],"compareEarnings":[{"period":"1week","weight":0.033},{"period":"1month","weight":0.0601},{"period":"3month","weight":0.0025},{"period":"6month","weight":0.0147},{"period":"1year","weight":0.1734},{"period":"ytd","weight":0.0388}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"乐普生物科技股份有限公司是一家主要从事医药产品销售及新药研发的公司。该公司聚焦于肿瘤治疗领域，尤其是靶向治疗及免疫治疗。该公司致力于通过抗体药物偶联物（ADC）技术开发平台开发创新型ADC。该公司的临床阶段候选药物涵盖靶向疗法药物和一种免疫治疗药物，具体包括MRG003、MRG002、CMG901、MRG004A、CG0070、MRG006A、MRG007、CTM012等。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070458},{"month":2,"riseRate":0.5,"avgChangeRate":0.087235},{"month":3,"riseRate":0.4,"avgChangeRate":-0.009016},{"month":4,"riseRate":0.8,"avgChangeRate":0.177486},{"month":5,"riseRate":0.6,"avgChangeRate":-0.004036},{"month":6,"riseRate":0.5,"avgChangeRate":-0.04556},{"month":7,"riseRate":0.5,"avgChangeRate":0.067498},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002458},{"month":9,"riseRate":0.5,"avgChangeRate":0.085192},{"month":10,"riseRate":0.25,"avgChangeRate":-0.14162},{"month":11,"riseRate":0.25,"avgChangeRate":0.007333},{"month":12,"riseRate":0.25,"avgChangeRate":-0.05091}],"exchange":"SEHK","name":"乐普生物-B","nameEN":"LEPU BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"乐普生物-B(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供乐普生物-B(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"乐普生物-B,02157,乐普生物-B股票,乐普生物-B股票老虎,乐普生物-B股票老虎国际,乐普生物-B行情,乐普生物-B股票行情,乐普生物-B股价,乐普生物-B股市,乐普生物-B股票价格,乐普生物-B股票交易,乐普生物-B股票购买,乐普生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"乐普生物-B(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供乐普生物-B(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}